Senator asks FDA chief for info relating to Genentech

Sen. Herb Kohl (D-WI) has asked commissioner Andrew von Eschenbach for info relating to the FDA's role in a decision by Genentech to limit availability of its cancer drug Avastin to certain drug compounding pharmacies. Kohl said some physicians have charged that Genentech is taking the step to boost sales of its Lucentis, which is much more expensive than Avastin. 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions